IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

CAESAREA, Israel, Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense^® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m. EDT and will conduct a conference call that will take place that day at 4:30 p.m. EDT. The conference call will be hosted by IceCure management who will be joined by Dr. Kenneth Tomkovich, Co-Primary investigator for IceCure's ICE3 clinical trial on cryoablation of small, low-risk breast cancer.

Dr. Tomkovich is a Diagnostic and Interventional Radiologist with Princeton Radiology and Director of Breast Imaging and Interventions at CentraState Medical Center, New Jersey. A prolific researcher, Dr. Tomkovich has authored or co-authored articles in several medical journals including Respiratory Medicine, Academic Radiology, Emergency Radiology, and the American Journal of Radiology.

Dr. Tomkovich presented interim data from the ICE3 clinical trial at the Radiologists Society of North America (RSNA) in 2021. His presentation titled "Primary Treatment of Low Risk Breast Cancers Using Image-Guided Cryoablation: A 6 Year Update of the ICE3 Trial" was selected to be featured in a daily bulletin by RSNA, the largest radiology society in the world with over 48,000 members in the United States, representing 31 radiologic sub-specialties sharing state-of-the-art radiological innovations.

Conference call:
August 15, 2022 at 4:30 pm ET
US: 1-888-642-5032
Israel/International: +972-3-9180609

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses the scheduling of a conference call and reporting its business and financial results as of and for the second quarter ended June 30, 2022. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:
Ronen Tsimerman
email: [email protected]

SOURCE IceCure Medical